Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Friday. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 17th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Supernus Pharmaceuticals in a report on Saturday, September 27th. Get Supernus Pharmaceuticals alerts:Get Our Latest Stock Analysis on Supernus PharmaceuticalsSupernus Pharmaceuticals Stock Up 0.8%Insider Transactions at Supernus PharmaceuticalsShares of NASDAQ:SUPN opened at $48.35 on Friday. Recommended StoriesReceive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.